IGHV4-34 superantigen and N-glycosylation motifs
| . | PVRL* . | PCNSL* . | DLBCL-ABC* . | DLBCL-GCB* . | P (across entities) . |
|---|---|---|---|---|---|
| IGHV4-34 super antigen motif | |||||
| Codon 6 (Q) | 1/26 (3.8) | 2/15 (13.3) | 2/79 (2.5) | 1/9 (11.1) | .237 |
| Codon 7 (W) | 0/26 (0) | 0/15 (0) | 2/79 (2.5) | 1/9 (11.1) | .256 |
| Codons 24-26 (AVY motif) | 4/35 (11.4) | 1/17 (5.9) | 7/79 (8.9) | 4/10 (40.0) | .034 |
| IGHV4-34 N-glycosylation motifs | |||||
| Disruption of CDR2 N-glycosylation motif | |||||
| Codon 57-59 (NHS) | 31/35 (88.6) | 12/17 (70.6) | 41/79 (51.9) | 41/79 (51.9) | .001 |
| Creation of a novel N-glycosylation motif in FR3 | |||||
| Codon 68-70 (NPS) | 5/35 (14.3) | 0/17 (0) | 4/79 (5.1) | 4/79 (5.1) | .198 |
| . | PVRL* . | PCNSL* . | DLBCL-ABC* . | DLBCL-GCB* . | P (across entities) . |
|---|---|---|---|---|---|
| IGHV4-34 super antigen motif | |||||
| Codon 6 (Q) | 1/26 (3.8) | 2/15 (13.3) | 2/79 (2.5) | 1/9 (11.1) | .237 |
| Codon 7 (W) | 0/26 (0) | 0/15 (0) | 2/79 (2.5) | 1/9 (11.1) | .256 |
| Codons 24-26 (AVY motif) | 4/35 (11.4) | 1/17 (5.9) | 7/79 (8.9) | 4/10 (40.0) | .034 |
| IGHV4-34 N-glycosylation motifs | |||||
| Disruption of CDR2 N-glycosylation motif | |||||
| Codon 57-59 (NHS) | 31/35 (88.6) | 12/17 (70.6) | 41/79 (51.9) | 41/79 (51.9) | .001 |
| Creation of a novel N-glycosylation motif in FR3 | |||||
| Codon 68-70 (NPS) | 5/35 (14.3) | 0/17 (0) | 4/79 (5.1) | 4/79 (5.1) | .198 |
Data are n/N (%).